12月5日 - ** 制药商Amylyx Pharmaceuticals AMLX.O股价盘前上涨1.8%至 14.75美元
** 该公司称，在治疗肌萎缩性脊髓侧索硬化症（ALS）的早期试验中，第一批患者对试验性药物AMX0114的耐受性普遍良好
** 公司表示，ALS 是一种致命疾病，会导致进行性肌无力和运动能力丧失。
** 早期试验招募了 12 名患者，没有发现与治疗有关的严重副作用 - AMLX
** 每四周向脊髓液中注射一次药物；旨在保护神经细胞，公司称
** 本月和一月将分别在加拿大和美国开始第二批患者注册 - AMLX
** 截至上次收盘，该公司股价年累计上涨约283%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.